Allergan Holdings Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ALLERGAN HOLDINGS, and what generic alternatives to ALLERGAN HOLDINGS drugs are available?
ALLERGAN HOLDINGS has one approved drug.
There are twenty US patents protecting ALLERGAN HOLDINGS drugs.
There are one hundred and thirty patent family members on ALLERGAN HOLDINGS drugs in forty countries and twenty-three supplementary protection certificates in sixteen countries.
Summary for Allergan Holdings
| International Patents: | 130 |
| US Patents: | 20 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Allergan Holdings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Holdings | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | RX | Yes | No | 9,675,587 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Allergan Holdings | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | RX | Yes | No | 8,344,011 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Allergan Holdings | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | RX | Yes | No | 9,789,125 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Allergan Holdings | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | RX | Yes | No | 11,311,516 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Allergan Holdings Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E042748 | ⤷ Try a Trial |
| Japan | 5852625 | ⤷ Try a Trial |
| Poland | 2298744 | ⤷ Try a Trial |
| Cyprus | 1120892 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Allergan Holdings Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2176234 | C02176234/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66549 07.02.2018 |
| 1725537 | C20170005 00225 | Estonia | ⤷ Try a Trial | PRODUCT NAME: ELUKSADOLIIN;REG NO/DATE: EU/1/16/1126 21.09.2016 |
| 1725537 | 122017000009 | Germany | ⤷ Try a Trial | PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919 |
| 1725537 | 132017000028006 | Italy | ⤷ Try a Trial | PRODUCT NAME: ELUXADOLINE O UN ENANTIOMERO, DIASTEREOMERO, RACEMATO FARMACEUTICAMENTE ACCETTABILE O SALI DELLO STESSO(TRUBERZI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1126, 20160921 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
